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Introduction

Chronic hepatitis B (CHB) virus infection is an epidemic that is
However, despite appropriate passive-active immunoprophylaxis, MTCT remains a concern and has been reported in approximately 8%-15% of infants who are born to highly viremic mothers, resulting in a significant incidence of infant chronic infection and adding to the large pool of patients with CHB in Asia. (6) (7) (8) Previous studies indicate the use of lamivudine (LAM) or telbivudine (LdT) during late pregnancy in highly viremic mothers can reduce MTCT, although the long-term fetal and infant safety has not been established. (7, 9, 10) Currently, tenofovir disoproxil fumarate (TDF) is not approved for the treatment of hepatitis B in China. A recent US report suggested that TDF might be used in the third trimester of pregnancy in preventing MTCT.(11) However, real-life observational data are lacking on the use of antiviral therapy in late pregnancy for preventing MTCT. In addition, the sample size in the currently published prospective trials for antiviral treatment in pregnancy involves only approximately 100 subjects in the treatment arm, which may not be large enough to capture the uncommon adverse events.
We conducted a prospective study with a sample size of 700 patients to assess the safety and efficacy of the third trimester use of LdT or LAM vs. no treatment, based on the patientphysician decision in a real-life MTCT prevention setting. 
Methods
Study Design
This was a prospective, open-label, interventional trial, in which patients were recruited from a tertiary care hospital, the Beijing Youan Hospital in China between January 2009 and March 2011. The trial was approved by the institutional ethics review committee and registered with ClinicalTrials.gov (No: NCT01743079). All subjects consented prior to screening for the study.
Pregnant subjects were screened for the following eligibility criteria: age between 20 and 40 years, gestational age between 26 and 28 weeks, HB-s antigen (HBsAg) and HB-e antigen (HBeAg) positivity, HBV DNA levels above 6 log 10 copies/mL and alanine aminotransferase (ALT) below the upper limit of normal (ULN = 40 IU/mL). The key exclusion criteria were coinfection with hepatitis C, D or E or HIV; evidence of hepatocellular carcinoma or cirrhosis; concurrent treatment with immune modulators, cytotoxic drugs or steroids; clinical signs of threatened miscarriage in early pregnancy; use of antiviral therapy prior to the pregnancy or during pregnancy; evidence of fetal deformity by ultrasound examination; or if the biological father of the child had CHB.(12) We did not enroll patients with elevated ALT because LdT or LAM treatment as a mono-therapy was not considered the optimal treatment for maternal active CHB. Pregnant women fulfilling the inclusion and exclusion criteria were offered participation in the study. Investigators explained the following key information to the patient and her family prior to the mother making a decision: 1) The standard MTCT prevention method is to administer HBIg and vaccine on time, which have approximately 90% successful rates. 2) To further reduce the MTCT rate in highly viremic mothers, antiviral therapy may be used, but there is a lack of long-term safety data. In addition, there is no guarantee of successful outcomes. 3) If the mother would like to be enrolled and receive antiviral treatment after week 28 of pregnancy, only LdT or Lam may be taken. LdT was more potent than LAM in reducing HBV DNA in a large, registration clinical trial but included only non-pregnant female patients. Thus, safety in pregnant women has not been well-established. LAM has much more short-term safety data in HBV mono-infected mothers and a larger database for HIV-infected mothers and infants.
However, antiviral resistance is more common in LAM-treated patients. After discussing the risks and benefits of LdT or LAM therapy during the third trimester with standard immunization to infants vs. clinical observation (no antiviral treatment) during pregnancy with standard immunization to infants, pregnant mothers were enrolled in the treatment or observation group based on patient's informed decision. Those who opted for antiviral therapy started on oral LdT 600 mg or LAM 100 mg (as per patients' wishes) daily between gestational weeks 28 to 30.
Tenofovir treatment was not discussed with patients in this study because it was not an approved CHB therapy in mainland China during the study period. With adherence to our standard of care, mothers receiving no treatment (NTx) also had the same follow-up schedule prior to the delivery as those who received antiviral therapy. After delivery, mothers taking LdT or LAM treatment discontinued the treatment at postpartum week 4 and received follow-up every four weeks for 12 weeks or until the ALT returned to normal if subjects had elevated ALT after the cessation of antiviral therapy, whichever was longer. Mothers were instructed not to breast-feed infants during the antiviral therapy because the concentration of LAM or LdT in the breast milk has not been fully studied. As the standard of care for all subjects, prenatal visits were scheduled as follows: baseline, every two weeks until the 36th week and then weekly until delivery. Tests for HBV serologic status, ALT and HBV DNA were repeated in four-week intervals prior to the due Hissen Bio-pharm Co., China) was administered within 6 h of birth. The second injection of the same dose of HBIg was administered at two weeks of age. The second and third doses of recombinant HBV vaccines were given at one month and six months of age, respectively. The infant's HBV serologic status and HBV DNA were tested at birth (prior to immunization) and again at week 52.
Outcome Measures and End Points
The two primary outcomes were (1) the safety and tolerability of LdT and LAM in mothers and infants, which included all adverse events (AEs) and drug discontinuation in patients who received at least one dose of a study drug. The data of mothers and infants who were lost to follow-up after delivery were still included for antepartum analysis of the drug safety. AEs were graded according to the Common Terminology Criteria for Adverse Events, version 3.0. As per protocol, ALT flares (>5 times baseline level or >10 times ULN) were considered severe adverse events (SAEs). The direct genome sequencing method was used for resistance surveillance of viral genotypic mutation(s) only in patients with virological breakthrough on antiviral therapy (defined as >1 log 10 increase from nadir). Perinatal and partum complications (e.g., hypertensive disorders in pregnancy, gestational diabetes mellitus, fetal growth retardation, premature delivery, premature rupture of membrane and postpartum hemorrhage) were included in the safety analysis. Safety reports for infants were tabulated using data acquired from infant followup visits (e.g., reports of birth defects and Apgar scores, measurements from growth charts and development milestones). ( 2) The MTCT rates in the treated and untreated group were an endpoint, which was defined as detectable levels of HBV DNA or HBsAg in the peripheral serum samples of infants at age 52 weeks. The secondary measurements were antiviral effects of LdT and LAM during the third trimester of pregnancy on controlling HBV viremia, defined as the percentage of mothers having pre-delivery serum HBV DNA reduction to levels of either partial control (< 6 log 10 copies/mL) or complete control ( <500 copies/mL, polymerase chain reaction; Shanghai Kehua Bioengineering, Co., Ltd., China; range of detection: 500 copies; 8 x log 10 copies/mL), maternal HBeAg loss/sero-conversion and HBsAg loss/sero-conversion rate (enzyme-linked immunosorbent assay; Shanghai Kehua Bioengineering, Co., Ltd.). In addition, infant HBsAg status and titers at birth and age of 28 weeks were also tested against the comparison of their status at the age of 52 weeks. For infants' HBsAg titers at birth, 5 IU has been recommended by our central laboratory system as a cut-off level for significance and high specificity.
Statistical Methods
Intention-to-treat (ITT) was defined as an analysis performed in all enrolled patients, including those with protocol deviations, but patients who withdrew consent prior to treatment were excluded. Patients lost to follow-up during the study were counted as treatment failures in ITT analyses. On-treatment analysis was defined as analysis performed for all enrolled patients, including those with protocol deviations, but those who withdrew consent prior to treatment, who were lost to follow-up or who discontinued the study for any other reason(s) were excluded.
ITT and on-treatment analysis of baseline characteristics and all end points were performed.
Baseline characteristics and laboratory results were summarized for the three groups by means of descriptive statistics, including percentage, means ±standard deviation (SD) and 95% confidence interval (95% CI). For the quantitative variable, the t test was used to compare group differences. For categorical variables, the χ 2 test was used for group comparisons. The 
Results
Study Population
Among 700 mothers enrolled, eight subjects withdrew consents prior to the baseline visit.
Forty-four subjects were lost to follow-up after the baseline, which included 19 mothers prior to the delivery and 25 mothers during the postpartum period, resulting in 648 mothers with a 52-week follow-up (LdT /LAM /NTx = 252/51/345). The patient disposition is shown in Figure 1 .
At least one dose of LdT was administered in 263 patients, and one dose of LAM was administered to 55 patients, resulting in 318 patients in the treated group at the baseline visit. The rest of the 374 subjects received no antiviral treatment and served as the control group. The baseline characteristics of the three study arms were similar and are shown in Table 1 . After the baseline visit, there were eight mothers in the treatment group and 11 mothers in the control group who withdrew from the study prior to the delivery. There were 686 infants born from 673 mothers (LdT/LAM/NTx = 257/53/363) in this cohort with 13 pairs of twins, and 661 infants completed 52 week follow-up. There were no significant differences in baseline demographics, and the clinical characteristics of the infants in the three study arms are shown in Table 1 . The mean (+SD) duration of treatment was 10.38 (+1.02) and 10.53 (+0.89) weeks for patients who received LdT and LAM therapy, respectively.
Safety of Mothers and Infants
Treatment with LdT or LAM was generally well tolerated by pregnant women. During the treatment period, eight mothers (LdT/LAM = 6/2) in the treatment group withdrew from the Table 2 ), there was no severe hepatitis flare (ALT > 10 x ULN or five times of baseline) were noted. All mothers followed the instructions of no breast-feeding during
LdT or LAM treatment. Thus, no safety data for breast-feeding on LdT/LAM are available in this study. The incidence and nature of AEs in infants of both groups were similar, and no significant differences were found in terms of infants' weights, heights or Apgar scores (Tables 1 12   and 3) . Congenital deformities was reported in 0.32% (95% CI: -0.31% to 0.95%) of infants in the treatment group (only one infant with unilateral cleft palate in the LdT-treated group), which did not significantly differ from the rate of 0.54% (95% CI: -0.22% to 1.31%) among infants in the untreated group (p>0.05). Two infants with congenital deformities were reported in the untreated group (one infant had six digits, and another one had talipes equinovarus).
Efficacy Assessment: Mothers
Prior to delivery, LdT-treated mothers had a mean serum HBV DNA decline > 4 log 10 copies/mL, resulting in a mean (SD) HBV DNA of 3.16 (1.59) log 10 copies/mL, compared with no significant change in HBV DNA levels for the untreated group (p < 0.001). Similarly, LAMtreated mothers had a mean serum HBV DNA decline > 3 log10 copies/mL resulting in a mean 13 copies/mL), resulting in viral breakthrough. There was no genotypic resistance mutant detected in the above five subjects during the course of antiviral treatment.
Efficacy Assessment: Infants
All infants in the study received HBIg with HBV vaccine within 6 h of birth and completed all vaccinations according to the protocol except for 25 infants (treated/untreated; n = 7/18) who were lost to follow-up when their age was four weeks or older. with HBV DNA levels above 6 log 10 copies/mL. They were HBsAg positive at birth with high HBsAg titers. In addition, there were no changes in the infants' HBsAg status and HBV DNA levels when comparing tests performed at the age of 28 weeks vs. those performed at the age of 52 weeks in all infants who completed the 52 week follow-up (Table 4) .
Discussion
In this study, we report the prospective data of LdT and LAM therapy for the prevention of MTCT. To our knowledge, this is the largest real-life study with 700 subjects enrolled to should be mandated. There were 1.6% of subjects who had mild CK elevation during LdT treatment in our study, but none in the LAM-treated group displayed CK elevation. However, they were all asymptomatic without EKG abnormality and considered by investigators as not clinically significant. The lower rate of CK elevation observed in our study may be due to the short duration of the LdT exposure. Although ALT flares at postpartum after cessation of LdT or LAM treatment were also common, none of the cases displayed severe flares in this large cohort.
Resistance surveillance with genotypic analysis has been emphasized by society guidelines when using LdT or LAM to treat viremic patients over 12 weeks. (18, 19) Our data suggest that in treatment-naïve mothers, antiviral resistance was uncommon when receiving antiviral treatment during late pregnancy to prevent MTCT because the treatment cessation generally breakthrough among patients on antivirals in this cohort, but all were due to the non-adherence to the medication. In our study, there were no genotypic mutants detected among patients with viral breakthrough on LAM or LdT therapy. It is possible that our laboratory did not detect emergent mutants at a low level of replication because of the sensitivity of the test in this study. (19) However, with the cessation of antiviral treatment at postpartum, the wild-type HBV is likely to re-populate and suppress mutants with resistance to the antiviral medication. Although drugresistant mutants can be selected for (20), the long-term consequence of low levels of antiviralresistant mutant replication remains unknown. However, we found that testing the HBV DNA level monthly before delivery was beneficial because monitoring treatment adherence was an important aspect of achieving HBV DNA levels below 6 log 10 copies/mL.
Several recent publications indicate that there are no differences in fetus/infant complication rates or birth defect rates when using LdT or LAM to treat pregnant women vs. no antiviral treatment. Hepatology Hepatology abnormality was 3.8%. However, there was no control group in this study. We believe that our data significantly contribute to the above data gap as we had a larger sample size and longer observation. Our study had 262 and 52 infants born to LdT-and LAM-treated mothers without safety concerns identified at 52 weeks of follow-up, respectively. We demonstrated that the treatment with LdT or LAM did not increase fetus/infant complications or birth defects compared with infants in the untreated group. Thus, this study supports the safe use of LdT and LAM in a real-life setting in highly viremic mothers.
Although the efficacy of LdT in reducing MTCT has been reported in several studies (9, 10) , the use of LAM on highly viremic mothers for the prevention of MTCT remains controversial.
Xu et al. reported that 18% of infants born to mothers receiving LAM in late pregnancy were infected with CHB. There was no significant difference in the MTCT rates between infants in the LAM treated vs. untreated group according to sensitivity analysis. (7) By both ITT and ontreatment analysis, our study indicated that the use of LAM in highly viremic mothers significantly reduced MTCT compared no treatment. Subjects in our study started on LAM approximately two to four weeks earlier than those mothers in Xu's study, resulting in predelivery maternal HBV DNA < 5 log 10 copies/mL. In contrast, subjects in Xu's study received LAM between 32 to 34 weeks of gestation and had significant viremia at delivery, resulting in a high MTCT rate. It appears that our early use of LAM may have a better chance to achieve maternal HBV DNA reduction to levels below the transmission threshold of 6 log 10 copies/mL.
A number of features are worth noting in the current study. Our trial provides the largest cohort examining the safety and efficacy of LdT and LAM treatment in late pregnancy. The study design simulated the decision-making process for antiviral therapy for pregnant women in LdT or LAM resistance.
In conclusion, our results indicate that HBsAg-positive mothers with HBV DNA > 6 log 10 copies/mL who received LdT or LAM treatment at gestation weeks 28-30 displayed a significant reduction in MTCT rate with comparable safety and efficacy. However, on-treatment ALT flares are common and should be monitored. Infants' HBsAg statuses at the age of 28 weeks were consistent with those at 52 weeks. Thus, the MTCT rate may be determined at the infant age of 28 weeks. Our data support the use of LdT or LAM during late pregnancy in highly viremic mothers for the purpose of reducing MTCT of CHB.
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